J&J and Sanofi's mul­ti­ple myelo­ma tit-for-tat con­tin­ues, as sub­cu­ta­neous Darza­lex wins com­bo ap­proval

J&J and Sanofi have gone back and forth in their mul­ti­ple myelo­ma tug-of-war. Ear­li­er this year, Sanofi notched an ap­proval of Sar­clisa in com­bi­na­tion with Am­gen’s Kypro­lis to try to out­flank the big con­glom­er­ate, but J&J is clap­ping back.

Wednes­day af­ter­noon, Am­gen an­nounced that the sub­cu­ta­neous ver­sion of J&J’s block­buster Darza­lex is al­so now ap­proved as a com­bo with Kypro­lis and dex­am­etha­sone. The green light came through for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma who had pro­gressed on one to three ear­li­er lines of ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER